Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication May 11, 2017
- Accepted for publication June 27, 2017
- Published online October 2, 2017.
Article Versions
- previous version (July 7, 2017 - 06:30).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- 1Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
- 2Department of Chemistry, Hunter College of the City University of New York, New York, New York
- 3PhD Program in Chemistry, Graduate Center of the City University of New York, New York, New York; and
- 4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
- For correspondence or reprints contact: Brian M. Zeglis, Hunter College of the City University of New York, 413 E. 69th St., New York, NY 10021. E-mail: bz102{at}hunter.cuny.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
- Biomimetic, smart and multivalent ligands for G-quadruplex isolation and bioorthogonal imaging
- Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy
- Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
- Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
- Target-responsive vasoactive probes for ultrasensitive molecular imaging
- Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins
- Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle
- {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 1